Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia (original) (raw)

This study assesses the cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide (R-FC) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Utilizing a base-case analysis over a 30-year horizon, R-FC was found to lead to increased progression-free survival (PFS) and overall survival (OS), with an incremental cost-effectiveness ratio (ICER) of $23,530 per additional quality-adjusted life-year (QALY) gained. These results indicate that R-FC is a financially viable option, supporting its position as a new standard of care in managing untreated CLL.